Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade In Vitro and In Vivo

Cancer Prevention Research

Volumn 5, Issue 4, 2012, Pages 631-643

  Rajendran, Peramaiyan ^a,d   Li, Feng ^a,d   Shanmugam, Muthu K ^a,d   Kannaiyan, Radhamani ^a,d   Goh, JenNee ^a,b,d   Wong, KwongFai ^b,d   Wang, Wei ^a,d   Khin, Ester ^a,d   Tergaonkar, Vinay ^c,d   Kumar, AlanPrem ^a,b,d   Luk, John M ^a,b,c,d   Sethi, Gautam ^a,b,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELASTROL; JANUS KINASE 1; JANUS KINASE 2; PROTEIN TYROSINE PHOSPHATASE; STAT3 PROTEIN; VANADIC ACID; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TRIPTERINE; TRITERPENE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; GENE PRODUCT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; ANIMAL; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 2; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TETRAZOLIUM SALTS; THIAZOLES; TRITERPENES; VANADATES;

EID: 84864835881     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0420     Document Type: Article

References (48)

1. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550-60.
2. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29: 2309-24.
3. Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009;29:10-7.
4. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009;15:3210-6.
5. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996;84:331-4. (Pubitemid 26058558)
6. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008;15:834-43. (Pubitemid 351736406)
7. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18:45-56.
8. Yu H, Jove R. The STATs of cancer- new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
9. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009;1171:59-76.
10. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006;1091:151-69. (Pubitemid 47092233)
11. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, et al. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 2002;37:63 -71.
12. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005;24:6406-17. (Pubitemid 41486474)
13. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, et al. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 2011;17:1425-39.
14. Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, et al. Celastrol inhibits proliferation and induces chemosensitization through downregulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol 2011;164: 1506-21.
15. Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007;27: 879-90. (Pubitemid 47261940)
16. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 2010;70:1951- 9.
17. Huang Y, Zhou Y, Fan Y, Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008;264:101-6.
18. Lu Z, Jin Y, Qiu L, Lai Y, Pan J. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 2010;290:182- 91.
19. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007; 109:2727-35. (Pubitemid 46482064)
20. Salminen A, Lehtonen M, Paimela T, Kaarniranta K. Celastrol: molecular targets of Thunder God Vine. Biochem Biophys Res Commun 2010;394:439- 42.
21. Morita H, Hirasawa Y, Muto A, Yoshida T, Sekita S, Shirota O. Antimitotic quinoid triterpenes from Maytenus chuchuhuasca. Bioorg Med Chem Lett 2008;18:1050-2. (Pubitemid 351187879)
22. Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 2010 Aug 2. [Epub ahead of print].
23. Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, Liu M, et al. Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med 2010;88:1243-53.
24. Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 2011;303:9-20.
25. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 2011;16: 1028-41.
26. Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G, et al. Capsaicin is a novel blocker of constitutive and interleukin-6- inducible STAT3 activation. Clin Cancer Res 2007;13:3024-32. (Pubitemid 46849579)
27. Xu MZ, Chan SW, Liu AM, WongKF, Fan ST, Chen J, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011;30:1229-40.
28. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009;50:1453- 63.
29. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81-3.
30. Brierley MM, Fish EN. Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 2005;25:733-44. (Pubitemid 43071210)
31. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88. (Pubitemid 30339203)
32. Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH. Inter-leukin- 6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res 2008;147:23-33. (Pubitemid 351626069)
33. Zauberman A, Zipori D, Krupsky M, Ben-Levy R. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. Oncogene 1999;18:3886-93. (Pubitemid 29358567)
34. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 1999;274:23013-9.
35. Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 2002;277:45680-7. (Pubitemid 36159180)
36. Han Y, Amin H, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK-positive anaplastic large-cell lymphoma. Blood 2006;108:2796-803.
37. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9:50 -63.
38. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513. (Pubitemid 32531347)
39. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19:2489-95. (Pubitemid 30339204)
40. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor- kB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109:2293 - 302.
41. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002;168: 466-74. (Pubitemid 34014150)
42. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-93.
43. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G. Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 2010;334: 285-93.
44. Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther 2010;9: 953-62.
45. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9. (Pubitemid 43166170)
46. Venkatesha SH, Yu H, Rajaiah R, Tong L, Moudgil KD. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J Biol Chem 2011;286:15138-46.
47. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, et al. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2010;7:17.
48. Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, Lawrence TS, et al. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys 2009;74:1217-25.